U.S. application Ser. No. 09/509,210, Arnould, filed Mar. 24, 2000. |
U.S. application Ser. No. 09/869,064, Arnould, filed Jun. 21, 2001. |
U.S. application Ser. No. 10/110,690, Wardleworth et al., filed Apr. 17, 2002. |
Evans et al., “Nanomolar-Affinity, Non-Peptide Oxytocin Receptor Antagonists,” J. Med. Chem., vol. 36, No. 25, 1993, pp. 3993-4005. |
Garcia et al., “Peptidomimetic Inhibitors of Ras Farnesylation and Function in Whole Cells”, J. Biol. Chem., vol. 268, 1993, pp. 18415-18418. |
Graham t al., “Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase”, J. Med. Chem. 1994; vol. 37, pp. 725-732. |
Kemp et al., “Studies of N-Terminal Templates for a-Helix Formation: Synthesis and Conformational Analysis of (2S,5S,8S,11S)-1-Acetyl-1,4-diaza-3-keto-5-carboxy-10-thiatricyclo[2.8.1.04.8]-tridecane (Ac-Hel1-OH)”, J. Org. Chem., 1991, vol. 56, pp. 6672-6682. |
Kohl et al., “Selective Inhibition of ras-Dependent Transformation by Farnesyltransferase inhibitor”, Science, vol. 260, Jun. 25, 1993, pp. 1934-1937. |
Lerner et al.; “Ras CAAX Petpidomimetric FT1-277 S lectively Blocks Oncogenic . . . Inactive Ras-Faf Complexes”; The Journal of Biological Chemistry, vol. 270, Nov. 1995, pp. 26802-26806. |
Magolda et al., “Design and Synthesis of Conformationally Restricted Phospholipids as Phospholipase A2 Inhibitors”, J. Cellular Biochemistry, 1989, vol. 40, pp. 371-386. |
Matsumura et al., “An Efficient Synthesis of (2S,4S)-Substituted 4-Mercaptopyrrolidine Derivatives”, Heterocycles, vol. 41, No. 1, 1995, pp. 147-159. |
Sunagawa et al., “A Novel Carbapenem Antiobiotic, SM-7338 Structure-Activity Relationships”, J. Antibiotics, vol. XLIII, No. 5, 1990, pp. 519-532. |
Sunagawa et al., “Synthesis and Antibacterial Activity of Novel Carbapenems with a Catechol of Hydroxypyridone Moiety”, J. Antibiotics, vol. 47, No. 11, 1994, pp. 1354-1358. |